Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Completed · Phase 1/Phase 2

Conditions studied: Unresectable Stage III or IV Malignant Melanoma

In brief

The purpose of this study is to identify candidate markers predictive of response and/or serious toxicity to BMS-734016 (MDX-010).

Key facts

Study ID

NCT00261365

Run by

Bristol-Myers Squibb

People needed

80

Starts

2005-11-01

Expected to finish

2007-10-01

Last updated by the study team

2016-09-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologic or cytologic diagnosis of unresectable State III or IV malignant melanoma (excluding ocular melanoma); A pre- and post-treatment fresh core or excision tumor biopsy must be provided.

Where it is running

• Comprehensive Cancer Center — Palm Springs, California, United States
• The Angeles Clinic And Research Institution — Santa Monica, California, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Local Institution — Aarhus C, Denmark
• Local Institution — Odense C, Denmark
• Local Institution — Jerusalem, Israel
• Local Institution — Bari, Italy
• Local Institution — Forlì, Italy
• Local Institution — Ravenna, Italy
• Local Institution — Rimini, Italy
• Local Institution — Oslo, Norway
• Local Institution — Lima, Lima Province, Peru
• Local Institution — Lima, Lima Province, Peru
• Local Institution — Gothenberg, Sweden
• Local Institution — Stockholm, Sweden

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.